Imugene’s $20 million boost and cancer trial updates

(7:42)

Imugene’s $20 million boost and cancer trial updates

(7:42)

Imugene CEO hails clinical milestone for HER-Vaxx cancer immunotherapy

(6:15)

Imugene thrilled as first patients dosed in VAXINIA MAST combination study

(5:15)

Imugene Receives Ethics Approval to Start Phase 2 Clinical Trial

(4:45)

ASX/ausbiz Biotech Unlocked with Imugene CEO Leslie Chong

(18:8)

Imugene Ltd (ASX:IMU) Investor Presentation 2017

(13:15)

ASX:IMU - Imugene Limited MD Leslie Chong on 6PR Bulls N' Bears Report

(3:14)

ASX:IMU - Imugene Managing Director, Leslie Chong on 6PR Bulls N' Bears Report

(3:6)

Executive Interview - Imugene

(4:32)

U.S. Coins Signature Auction - September 2015

(3:54)

Magnis Energy Technologies on Share Café Webinar: MicroSmall Cap \

(29:5)

ASX:IMU - Imugene Limited Managing Director Leslie Chong on 6PR Bulls N' Bears Report

(3:12)

MHOR Asset Management - James Spenceley Investor Presentation 2017

(14:44)

Imugene's Founder and Executive Chairman's keynote speech at Emerging Small Caps Summit 2021

(19:6)

Heritage Auctions - Chris Dykstra Interview

(4:20)

Interview State of Play in Immuno Oncology V1 0 Final Delivery 1280 x 720

(17:39)

Imugene doses first patient in phase-two study of cancer vaccine

(4:3)

Channel 7 News Exclusive

(1:26)

Oncology outlook: ASX small caps driving innovation in cancer treatment

(4:26)

Imugene achieves ‘complete response’ with mid dose cancer trial

(7:36)

Talking Business with Leon Gettler Interview with Leslie Chong from Imugene

(37:53)

VERIFY: Here's why your misprinted $20 could be worth $500

(1:23)

Is a $20 Gaming Keyboard Any Good??

(5:54)

$20 Mic Review!

(10:16)

Magnis Charges the Company Battery

(9:21)